Connect with us

Cancer

Racial disparities seen in care after abnormal mammograms

Published

on

Despite similar availability of diagnostic technologies to women of different racial and ethnic groups, significant disparities were seen in who actually received same-day diagnostic services and biopsies after abnormal mammogram findings, new research shows.

Even when breast-care facilities had the necessary technology and capabilities, minority groups were less likely than white women to receive diagnostic imaging on the same day as an abnormal screening result.

Black women in particular were less likely to receive same-day biopsies, compared with white women.

“We’re looking at how the diagnostic workup process might contribute to the population disparities we see with breast-cancer outcomes,” said Dr. Marissa Lawson, assistant professor of radiology at the University of Washington School of Medicine.

“It was surprising to find similar availability (of technologies) across racial and ethnic groups. But we still saw big differences in who was getting those same-day services.”

The retrospective study spanned nearly 11 years, from January 2010 to December 2020. The data represented more than 1.1 million female patients ages 40-89 and more than 3.5 million screening mammograms. The patients were seen in six U.S. states at 136 screening facilities that, as members of the Breast Cancer Surveillance Consortium, make data available for study.

With the multilevel analysis, the researchers hoped to shed light on how factors such as race and ethnicity, household income and neighbourhood educational attainment affected access to, and use of, breast-cancer diagnostics.

In the study, they first identified which consortium facilities offered onsite access to both standard-care and advanced diagnostics and biopsy. They then measured patients’ access to these capabilities, discerned which screening mammograms yielded an abnormal result, and evaluated those patients’ receipt of diagnostic imaging and biopsy on the same day and within 90 days at facilities that had the technology and capability onsite.

The researchers adjusted for several potentially influential factors such as patient breast density, biopsy history, personal and family history of breast cancer.

Asian, Black and Hispanic/Latinx patients received fewer same-day diagnostic services after undergoing a screening mammography with abnormal results at facilities offering any diagnostic or biopsy services. Patients who lived in the lowest-income neighbourhoods were 58 per cent less likely to have same-day diagnostic evaluations than those living in the highest-income neighbourhoods.

Notably, Lawson said, rural-resident patients were more likely to receive same-day diagnostic services than were urban residents.

Black patients and those who lived in a relatively lower median income were less likely than white patients to receive same-day biopsy at a capable facility. However, Hispanic/Latinx patients were more likely than white patients to receive same-day biopsy.

“Getting a screening mammogram is an anxiety-inducing experience for a lot of people, and most patients I encounter want their results as soon as possible,” Lawson said.

“If you’re able to do a diagnostic workup on the same day, instead of making them wait to schedule a follow-up visit — which might create a headache with work or transportation — that’s better for the patient. And if treatment is advised based on imaging and biopsy, we should do all we can to shorten the time between screening and treatment (for those diagnosed with breast cancer).”

The authors acknowledged several limitations, including a study population that might not be nationally representative of women’s education and rural residency. Variables that might affect patients’ ability to take advantage to clinic services, such as employment, insurance status, transportation barriers and childcare needs, were not included in the analyses.

It also is unknown whether individual patients declined the opportunity for same-day services or were not offered such services.

Insight

AI cuts interval breast cancers in Swedish trial

Published

on

An AI tool cut interval breast cancers by 12 per cent in a Swedish screening trial of more than 105,000 women.

The study also found 27 per cent fewer aggressive breast cancers detected at screening when AI was used.

Interval cancers are cancers found between routine screening appointments because they were missed at the original scan. They are often more dangerous and linked to higher death rates than cancers found at screening.

The MASAI trial is described as the first large randomised study to test whether AI can improve mammography screening, which uses low-dose X-rays to examine breast tissue for signs of cancer.

The AI tool, called Transpara Detection and developed by ScreenPoint Medical, supported radiologists in analysing mammography images.

Earlier results from the same trial showed that Transpara Detection increased cancers found by 29 per cent and reduced radiologist workload by 44 per cent compared with standard double-reading, where two radiologists independently review each scan.

The latest findings indicate higher accuracy with AI support. Sensitivity, the ability to detect cancer, was 6.7 percentage points higher in the AI group while specificity, the ability to rule out healthy cases, was maintained. Results were similar across age groups and breast density levels.

Women screened with AI had 16 per cent fewer invasive interval cancers and 21 per cent fewer large interval cancers than those in the standard screening group.

The system also helps doctors assess risk more precisely by subdividing suspicious findings into BI-RADS 4 categories A, B and C. BI-RADS (Breast Imaging Reporting and Data System) is a standardised scale that guides whether a patient needs closer monitoring, further tests or treatment.

Continue Reading

Insight

Study links changing population to low London screening rates

Published

on

London’s shifting population is holding down breast screening uptake, experts have said, with the capital at 62.8 per cent in 2024, below the NHS’s acceptable 70 per cent threshold.

The London Assembly Health Committee recently heard that the capital faces distinct challenges compared with the rest of the country and that these issues must be addressed.

Josephine Ruwende, a cancer screening lead at NHS England, said frequent moves within the rented sector and the cost-of-living crisis pushing people out of London had made it difficult to reach eligible patients, which she described as “population churn”.

She said: “This is people changing addresses and then not updating their GP, this then affects the invitation process because GP details are used to identify individuals who are eligible.

“In boroughs where we have the highest population churn, we see it strongly associated with lower uptake.”

She noted that even in the wealthiest boroughs there can be high levels of movement, with around 40 per cent of residents changing address within a year.

Such areas also tend to have more people who own second homes or spend long periods abroad, making it harder for the NHS to keep contact details up to date.

As a result, screening invitations may be sent to out-of-date addresses or to people who are overseas.

Leeane Graham, advocacy lead at Black Women Rising, which supports women of colour with a cancer diagnosis, said there were cultural barriers, fear and a mistrust of the health service due to previous experience within communities.

She said: “If you’ve never been for a breast screening before, the thought of having a mammogram can be really, really terrifying.”

Helen Dickens, from Breast Cancer Now, said other reasons included a lack of understanding of breast screening, along with concerns about discomfort, trust and practical issues such as travel.

She said: “We have amazing public transport and we feel that we’ve got great accessibility, but we also know that we don’t have screening centres in every borough.

“We know that for some women that barrier of transport and access will still be a really big reason why they’re not attending screenings.”

NHS London launched its first screening campaign last year in response to the figures, aiming to increase detection at an earlier stage.

Continue Reading

Insight

Period blood screening could boost cervical cancer checks

Published

on

Testing period blood for signs of cervical cancer could offer an accurate, convenient screening option for women who avoid clinic appointments, researchers say.

The current NHS test involves a nurse or doctor taking cells from the cervix, yet a third of those invited do not attend.

A study of the new test, which can be done at home, used blood collected on a cotton strip attached to a standard sanitary pad.

In research involving more than 3,000 women aged 20 to 54 years, Chinese investigators compared testing period blood collected on mini-pads with samples taken by clinicians.

Results were shared via a dedicated app.

When analysed in the lab, blood testing was nearly as good at identifying people with disease as other methods, and very good at ruling out those without it.

Cervical screening appointments are offered to all women, and anyone with a cervix, every five years between ages 25 and 64 in the UK.

Screening looks for high-risk human papillomavirus, a virus that can cause cancer.

A nurse or doctor carries out the test using a speculum to access the cervix.

However, five million women are not up to date, for reasons including fear, pain and discomfort.

“Cervical screening can be difficult for some women for many reasons, like if they have had a bad previous experience, they are menopausal, they have a physical or learning disability, cultural barriers, or are a survivor of sexual violence,” said Athena Lamnisos from charity The Eve Appeal.

Younger women, those with disabilities, and people from ethnic minority communities and LGBT+ groups are more likely to miss appointments.

Researchers say using menstrual blood for HPV testing is convenient, respects privacy and reduces discomfort.

Anyone who tests positive for HPV would be sent for a colposcopy, a close examination of the cervix with a magnifying instrument to look for pre-cancerous cells.

Experts caution that period blood tests are not an immediate alternative to current screening because only women who menstruate could use them.

Some also note the study may have overestimated performance because not all participants had a biopsy to double check results.

Sophie Brooks, health information manager at Cancer Research UK, said it was encouraging to see research exploring new ways to make screening more accessible.

She said testing menstrual blood for HPV was an interesting, non-invasive approach but more research in diverse groups is needed to see how it could fit into existing programmes.

Athena Lamnisos added that it was exciting to see more acceptable ways of offering a potentially life-saving test.

“People have different barriers and concerns about screening, so being able to offer a choice of different methods could be very positive for some who are eligible for screening but don’t currently attend,” she said.

The NHS is already sending at-home test kits to women in some areas of England who have missed several screening appointments.

These DIY kits, containing a vaginal swab, will be sent out more widely at some point this year.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.